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The increased trend of antimicrobial resistance has become a global threat to human security, caus-ing serious negative impacts on human, animal and environment. Inappropriate uses of antimi-crobial are main drivers of the emergence of resistant bacteria [1].Combating AMR requires in–
country multi–sectoral actions and global collective efforts using “One Health” approach.
The Thai National Strategic Plan on AMR (2017–2021) was developed through a full engagement of stake-
holders and National Health Assembly processes [2]. The Thailand Cabinet endorsed it in August 2016. 
Two out of the five targets are 20% and 30% reduction in antimicrobial consumption in human and an-
imal by 2021, respectively (see Box 1).
To optimize use of antimicrobial agents in human and animal, as recommended by the WHO Global Ac-
tion Plan [3], countries need to develop a sustainable system which monitors their consumption and dis-
seminate the information for policy decision. For example, France had a high human antibiotic use in the 
EU, and implemented a national campaign which resulted in a significant reduction in consumption [4]. 
This paper reviews international approaches on surveillance of antimicrobial consumption in human and 
animal, analyzes antimicrobial sales reporting systems and assesses how the surveillance system can be 
developed and sustained in Thailand.
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Box 1 Goals of the National Strategic Plan for AMR
By 2021:
1. 50% reduction in AMR morbidity
2. 20% reduction in antimicrobial consumption in humans
3. 30% reduction in antimicrobial consumption in animals
4. 20% increase of public knowledge on AMR and awareness of appropriate use of antimicrobials
5.  Capacity of the national AMR management system is improved to level 4 (measured by the 2016 WHO’s Joint 
External Evaluation for International Health Regulation 2005)
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ANTIMICROBIAL CONSUMPTION IN HUMAN 
AND ANIMAL: REVIEW OF INTERNATIONAL 
APPROACHES
Human consumption
Since 2011, European countries have been developing a surveil-
lance system for human. The European Surveillance of Antimi-
crobial Consumption Network (ESAC–Net) [5], covers 30 Euro-
pean Union and European Economic Area (EU/EEA) countries. 
It provides cross–country analysis and information is fed back to 
member countries to inform policy, as well as making publicly 
assessable information through the interactive database.
Data sources are either national sales of antimicrobials or reim-
bursement data available from health insurance systems. These data disaggregate consumption by com-
munity (ambulatory care) and hospital care (Table 1).
The surveillance system may cover hospital or community levels [6]. Monitoring consumption in hospi-
tal settings is useful for impact assessment of AMR leading to attribution of morbidity and mortality on 
health care cost and for micro–policy decision on rational use. Monitoring consumption in community 
is more complex than a hospital setting, where national sales data to communities are used for estima-
Reviews of international experiences in 
particular ESAC and ESVAC found use-
ful and applicable to developing coun-
tries, although there is a need to estab-
lish or strengthen sales data systems. 
System analysis of legal framework and 
reporting systems that captures antimi-
crobials sales data contributes to the 
design of Surveillance of Antimicrobial 
Consumption.
Table 1. Two data sources used by ESAC–Net and ESVAC: reimbursement vs sales data
Country reimbursement data antimiCrobial sales data
Human, 
community 
uses
Human, 
hospital 
uses
Human, 
combined 
community and 
hospital uses
Human, 
community 
uses
Human, 
hospital 
uses
Human, 
combined 
community and 
hospital uses
Animal 
uses
Austria X X
Belgium X X X
Bulgaria X X X
Croatia* X X
Cyprus X X
Czech Republic X X
Denmark X X X
Estonia X X X
Finland X X X
France X X X
Germany X X
Greece* X X
Hungary X X
Iceland X X
Ireland X X X X
Italy X X X
Latvia X X X
Lithuania X X X
Luxembourg X X X
Malta* X X
Netherlands X X X
Norway X X X X X
Poland X X
Portugal X X X X
Romania* X
Slovakia X X X
Slovenia X X X X X
Spain X X
Sweden X X X
United Kingdom X X
*No data in animals.
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tion. A majority of developing countries do not compile national sales data to communities. Alternative 
ways of capturing antimicrobial use are surveys of pharmacies, sentinel in specific sites or prospective 
household survey.
Animal consumption
The European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project was established in 
2009 [7]. It reports antimicrobial consumption in animal by collecting sales data of veterinary antimicro-
bials in 26 countries, which covers 95% of total food–producing animal populations.
The data sources came from wholesalers (17 countries), marketing–authorization holders (4 countries), 
both wholesalers and marketing–authorization holders (2 countries). Some countries provide feed mill 
data (Table 1) [7]. In all countries, it is mandatory by Law for pharmaceutical operators to report their 
sales data to the national authority, except in France, Hungary, Netherlands and Spain.
Analysis of data sources: reimbursement vs sales data
As seen in Table 1, antimicrobial sales data for human use is the main source in a majority of the 30 EU/
EEA countries. These data are able to be disaggregated by community and hospital uses; while all coun-
tries are reliant on sales data for antimicrobial agents used in animals. Most European countries had 
achieved universal health coverage; still there are limitations in capturing antimicrobial consumption from 
reimbursement databases. In developing countries with limited population coverage by insurance schemes, 
more limitation of reimbursement data for estimate of antimicrobial consumption is expected.
This indicates that development of the surveillance system requires strengthening of antimicrobial sales 
data for both humans and animals. Reviews found that approaches used by EU/EAA countries can be ap-
plied to developing countries given there is a good antimicrobial sales data systems in both sectors.
UNDERSTANDING THE LANDSCAPE OF DRUG AUTHORIZATION IN 
THAILAND
Legal frameworks and actors
Two laws govern the distribution of antimicrobials for human and animals: the 1967 Drug Act responsible 
by Thai Food and Drug Authority (Thai–FDA); and the 2015 Animal Feed Quality Control Act, responsible 
by Department of Livestock Development. It is noted that a majority of antimicrobials used in livestock are 
consumed through medicated feeds, and much less on finished products mostly applied to pets.
Key actors are importers, local manufacturers and pharmacies which are authorized to sell antimicrobials 
by Thai–FDA. Antimicrobials can be used upon prescription, but in practice the requests from custom-
ers and farmers could influence dispensing in private pharmacies. A major loop–hole in enforcing the 
Drug Act is the lack of effective measures and monitoring systems for antibiotic distribution especially 
active pharmaceutical ingredients (API).
Reporting sales data by operators
There are two mandatory sales reporting systems by the importers and manufacturers. First is the four–
monthly report of sales and distribution of potentially abused medicines by consumers, such as steroids, 
tramadol and dextromethorphan. This system is designed for tight control of distribution of these medi-
cines to prevent drug abuse. Second an annual report of production and importation of all pharmaceuti-
cal products where historically Thai–FDA did not request to provide distribution details.
To facilitate development of surveillance system, the existing two reports needs to revise in order to track 
the distribution of antimicrobials from productions/importation to users. However, the Thai–FDA has to 
issue regulations to add highly potentially antibiotics to the four–monthly report. Moreover, a greater re-
Producing meaningful and user–friendly information on magnitude and profile of antimicrobial con-
sumption and effective dissemination contribute to public and policy maker awareness, effective 
interventions and support sustaining Surveillance of Antimicrobial Consumption.
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liance on the annual report on production and importation with volumes and values of product and it 
requires them to report data on distribution channel. There is a gap which is the lack of reporting on the 
production of medicated feeds. Figure 1 presents the distribution channels.
With reference to reviewed information from ESAC and ESVAC, the planned Thailand systems where 
data sources on total sales for human are the combine of community and hospital levels and sales data 
for animal happens to be similar to Iceland (Table 1) where antimicrobials sales data are available on 
combined community and hospital care in humans; and totals are available for animal use. The break-
down by community and hospital use will be discussed further in the subsequent section.
Key parameters in the electronic reporting will include: the operator’s unique ID; pharmaceutical product 
unique ID with reference to the License ID assigned by Thai–FDA; Anatomical Therapeutic Chemical 
(ATC) classification); quantity and value including package size; doses; and forms. The objectives are to 
estimate human consumption as measured by Defined Daily Dose (DDD) and animal consumption as 
measured by milligram of antibiotic.
DEVELOPMENT OF SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION: 
METHODOLOGICAL APPROACHES FOR THAILAND
Currently, there is no system to monitor consumption of antimicrobial in Thailand. The Thai Surveillance 
of Antimicrobial Consumption (Thai SAC) is developed to fill the gap, which provides a 2017 baseline 
consumption and a long term monitoring process. In 2017, grants from USAID, WHO and FAO had been 
approved for research and development of the Thai surveillance system. Research team comprises of Thai–
FDA, Department of Livestock Development, universities and International Health Policy Program of the 
Ministry of Public Health. Systems analysis was conducted to understand the distributional channel, le-
gal framework and sales reporting systems; all forms the basis of the surveillance system development.
All medicines in the Thai–FDA registration database are assigned with ATC classification code for human 
drugs and ATCvet for veterinary medicinal products. The scope of surveillance system will cover antimi-
crobials at least for systemic use, J01 in human and QJ01 in animal.
The design of Thai Surveillance of Antimicrobial Consumption is based on national sales data, which is 
a mandatory report by importers and manufacturers to the Thai–FDA; as use data by clinical conditions, 
age and gender are not readily available.
The antimicrobial sales data will be verified for their adequacy, accuracy and completeness before analy-
sis. In human, antimicrobial consumption is measured by DDD per 1000 inhabitants–day [8]. The con-
sumption of antimicrobials in animal is measured by milligrams of API per population correction unit 
Figure 1. Distributional channels by 
antimicrobial agents. This study 
covers solid line which includes 
antibiotic sales data from importers 
and manufactures. The dotted line 
distributions are outside the scope 
of this study.
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(PCU). The PCU is the estimated weight for each animal 
species at treatment of livestock and of slaughtered animals 
at import and export for fattening and slaughter [7]. As 
there is no PCU in Thailand, we will use PCU following 
the ESVAC to facilitate international comparison.
CHALLENGES AND SOLUTIONS
A few challenges are identified for improvement of method-
ological approaches. Development of Surveillance of Antimi-
crobial Consumption relies on two sets of parameters: the 
numerators are total antimicrobial sales for human and ani-
mal consumption; the denominators are the total human and 
animal population.
The numerators
The completeness and accuracy of reporting by operators, though mandatory, is an initial challenge. How-
ever, electronic submission with reference to the unique identification number of each ATC code would 
facilitate accuracy of reporting.
There are total 774 importers and 184 manufactures; for which representative samples of operators se-
lected for on–site verification. This will gradually improve the quality of reports. Command and control, 
though a mandatory requirement by Thai–FDA, may not work well. Rather, effective communication be-
tween Thai–FDA and the operators and social recognition of their contributions to surveillance data are 
essential for adherence to quality report.
We assume that the total antimicrobial production and importation (though certain unknown size of re-
ported illegal importation and production) minus total exports is the total consumption in both sectors. 
Although there is variation in annual stock, in an efficient pharmaceutical market, the stock level should 
be constant.
The annual report by operators does not disaggregate by community, hospital and animal species. For 
human antimicrobials, we plan to disaggregate by using national insurance reimbursement data set or 
surveys of organisations. Antimicrobial consumption by key species of food animals is important for spe-
cific policy intervention, efforts are planned to disaggregate data by special surveys, including the estimate 
of total consumption in the aquaculture.
The off–label use of human antibiotics in pets and plants in particular citrus trees for the treatment of 
Greening Diseases [9] is commonly observed in Thailand; efforts are under way to investigate sources and 
magnitude of antibiotic use in pets and plants with supports from FAO by this research program.
The denominators
The Department of Livestock Development has yet to strengthen the data systems for accurate statistics 
on the total number of livestock by species. Not all livestock are raised through commercial standard 
farming systems, estimate size of local backyard farming contributes to accurate consumption per PCU. 
Estimate total national number of pets, most common are dogs and cats, and total PCU in aquaculture 
are the future research agenda.
The sustainability of the surveillance system
Sustainability of the surveillance system not only depends on the mandatory reporting system, other en-
abling factors are for example effective communication with the operators, user friendly electronic sub-
mission, systems which facilitate e–submission and safeguard confidentiality of sales data.
Relevant authorities had fully involved in the surveillance system design and development; this ensures 
long term sustainability in particular the IT systems. Policy decision based on evidences and publicly 
accessible report foster political support for a sustainable Thai Surveillance of Antimicrobial Consump-
tion.
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Photo: from the International Health Policy Program, Ministry of Public 
Health, Thailand, taken by Phanit Phacharaphimansakul (used with 
permission)
V
IE
W
PO
IN
TS
Acknowledgments: The authors wish to thank USAID, FAO and WHO Country Office Thailand, for supporting 
the development of Thai Surveillance of Antimicrobial Consumption program. We thank our researchers from 
Thai–FDA, Department of Livestock Development and National Drug Account research team and the faculty of 
Veterinary Science, Mahidol University for their contributions.
Funding: None.
Authorship contributions: All authors contributed to the design of the study. VT and AS drafted the manuscript. 
BC, NS, RS, SJ and VS contributed to the development of all sections of the manuscript. VT further revised the 
manuscript. All authors reviewed and approved the final revised version.
Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/
coi_disclosure.pdf (available upon request from the corresponding author) and declare no conflict of interest.
CONCLUSION
In responses to AMR, the Thai national surveillance system is critical for monitoring total consumption 
for which effective policies can be introduced to curb down excessive consumption. The current design 
disaggregates human consumption by level of care such as hospital and pharmacies; however point prev-
alence surveys are needed to estimate consumption by clinical conditions, age and gender. The current 
design does not differentiate consumption by animal species; further monitoring of veterinary prescrip-
tion support consumption by animal species.
Reviews of international experiences and the analysis of how to design a Thai Surveillance of Antimicro-
bial Consumption are useful to developing countries to apply to suit the national data systems. The Po-
litical Declaration of the High–Level Meeting of the UNGA on AMR in September 2016 which calls for 
“Improve surveillance and monitoring of AMR and the use of antimicrobials to inform policies” [10] puts 
pressure on countries to develop surveillance system and ensure its use for policy decision.
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